Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Meningioma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07533942
What this trial is testing

JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

Who this might be right for
Meningioma
Jazz Pharmaceuticals 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03604978
What this trial is testing

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

Who this might be right for
Grade 2 MeningiomaGrade 3 MeningiomaRecurrent Meningioma
National Cancer Institute (NCI) 38
Testing effectiveness (Phase 2)Looking for participantsNCT07150806
What this trial is testing

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Who this might be right for
Recurrent Meningioma
Joshua Palmer 30
Testing effectiveness (Phase 2)Looking for participantsNCT06275919
What this trial is testing

Regorafenib for Recurrent Meningioma (MIRAGE Trial)

Who this might be right for
Meningioma, Malignant
Istituto Oncologico Veneto IRCCS 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT04659811
What this trial is testing

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

Who this might be right for
Grade I Meningioma, AdultGrade II Meningioma, AdultGrade III Meningioma, Adult+1 more
Nancy Ann Oberheim Bush, MD 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT02648997
What this trial is testing

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Who this might be right for
Meningiomas
Dana-Farber Cancer Institute 40
Not applicableNot Yet RecruitingNCT07428213
What this trial is testing

Measurement of PSMA Expression in Vivo in Recurrent Meningiomas by PET Imaging: a Preliminary Study to a Therapeutic Trial Using Radioligand Therapy (RLT)

Who this might be right for
Meningioma
Hospices Civils de Lyon 40
Not applicableStudy completedNCT00890435
What this trial is testing

Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial

Who this might be right for
Brain and Central Nervous System TumorsLeukemiaUnspecified Adult Solid Tumor, Protocol Specific+1 more
Children's Oncology Group 53
Testing effectiveness (Phase 2)Study completedNCT06668987
What this trial is testing

The Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma

Who this might be right for
MeningiomaBoron Neutron Capture Therapy
Heron Neutron Medical Corp. 10
Testing effectiveness (Phase 2)Looking for participantsNCT02523014
What this trial is testing

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Who this might be right for
Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
Alliance for Clinical Trials in Oncology 124
Not applicableStudy completedNCT02162732
What this trial is testing

Molecular-Guided Therapy for Childhood Cancer

Who this might be right for
NeuroblastomaMedulloblastomaGlioma+16 more
Giselle Sholler 186
Testing effectiveness (Phase 2)Study completedNCT00045734
What this trial is testing

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

Who this might be right for
Adult Grade I MeningiomaAdult Grade II MeningiomaAdult Grade III Meningioma+3 more
National Cancer Institute (NCI) 23